Drugs

Chicago Cannabis Leaders Launch "Green Rose Advisors" Providing Consulting Services for Cannabis Entrepreneurs in Illinois and Around the United States.

Retrieved on: 
Tuesday, August 3, 2021
Cannabis, Cannabis smoking, Entheogens, Euphoriants, Psychoactive drugs, Drugs, Cannabis in Illinois

CHICAGO, Aug. 3, 2021 /PRNewswire/ --A group of Chicago cannabis leaders launched Green Rose Advisors ( https://www.greenroseadvisors.com ) a consulting firm offering expertise and resources to social equity cannabis entrepreneurs in Illinois and around the United States.

Key Points: 
  • CHICAGO, Aug. 3, 2021 /PRNewswire/ --A group of Chicago cannabis leaders launched Green Rose Advisors ( https://www.greenroseadvisors.com ) a consulting firm offering expertise and resources to social equity cannabis entrepreneurs in Illinois and around the United States.
  • Now they are offering additional consulting services and resources to help construct and operate dispensaries, craft growers and infusers as well.
  • Green Rose Advisors launched the same week the first social equity lottery was held in Illinois for 55 dispensary licenses.
  • Morreale was also co-founder and the longest serving chairman of the Medical Cannabis Alliance of Illinois (now the Cannabis Business Association of Illinois).

Yuyu Pharma Signs Exclusive Distribution Agreement with Novartis Korea for Domestic Distribution Rights in Korea for Lamisil®, Lescol® XL and Tegretol®

Retrieved on: 
Tuesday, August 3, 2021
Health sciences, Drugs, Health care, Yuyu, Carbamazepine, Novartis, Tablet

"With their marketing capabilities and a strong compliance system, we believe Yuyu Pharma is the ideal partner.

Key Points: 
  • "With their marketing capabilities and a strong compliance system, we believe Yuyu Pharma is the ideal partner.
  • Wonsang Yu, CEO of Yuyu Pharma said, "We at Yuyu emphasize the importance of good business practices and compliance.
  • We thank Novartis Korea for entrusting us with these important products and will continue to meet the needs our customers and patients."
  • The Tegretol series consists of Tegretol slow-release film coated tablets, Tegretol tablets, and Tegretol syrup.

Peels™ Debuts The Purest And Safest CBD On The Planet Made From Orange Peels, Guarantees Zero THC

Retrieved on: 
Tuesday, August 3, 2021
Drugs, Cannabinoids, Natural phenols, Resorcinols, Analgesics, Anticonvulsants, Cannabidiol, CBD

With both awards and certifications from Clean Label Project , Peels CBD Oil is the purest and safest CBD product on the market.

Key Points: 
  • With both awards and certifications from Clean Label Project , Peels CBD Oil is the purest and safest CBD product on the market.
  • "We're extremely proud of our CBD Oil and we know Peels is going to revolutionize the way people view and use CBD," continued Hetherington.
  • Peels offers the purest, safest CBD on the planet made from orange peels offering the highest quality, lowest risk cannabinoid product on the market.
  • Headquartered in Los Angeles, Peels is a data and science-driven CBD companydelivering better-for-you CBD wellness products.

CytoDyn Receives Clearance from Brazil’s ANVISA to Commence Phase 3 Trial for Severe COVID-19 Patients

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, FDA, Health, Clinical trials, Health sciences, Leronlimab, Health, Drugs, COVID-19, Long Covid, PASC, CCR5 receptor antagonist, Leronlimab, CytoDyn, LERONLIMAB, CYTODYN

This Phase 3 trial will be conducted in up to 35 clinical sites with 612 patients who are hospitalized and in need of oxygenation support.

Key Points: 
  • This Phase 3 trial will be conducted in up to 35 clinical sites with 612 patients who are hospitalized and in need of oxygenation support.
  • Additionally, ANVISA is reviewing another protocol submitted for a second clinical trial for 316 critically ill COVID-19 patients.
  • After completing two clinical trials with COVID-19 patients (a Phase 2 and a Phase 3), CytoDyn initiated a Phase 2 investigative trial for post-acute sequelae of SARS COV-2 (PASC), also known as COVID-19 Long-Haulers.
  • CytoDyn also completed a Phase 2b/3 investigative trial with leronlimab used as a once-weekly monotherapy for HIV-infected patients.

Yuyu Pharma Signs Exclusive Distribution Agreement with Novartis Korea for Domestic Distribution Rights in Korea for Lamisil®, Lescol® XL and Tegretol®

Retrieved on: 
Tuesday, August 3, 2021
Health sciences, Drugs, Health care, Yuyu, Carbamazepine, Novartis, Tablet

"With their marketing capabilities and a strong compliance system, we believe Yuyu Pharma is the ideal partner.

Key Points: 
  • "With their marketing capabilities and a strong compliance system, we believe Yuyu Pharma is the ideal partner.
  • Wonsang Yu, CEO of Yuyu Pharma said, "We at Yuyu emphasize the importance of good business practices and compliance.
  • We thank Novartis Korea for entrusting us with these important products and will continue to meet the needs our customers and patients."
  • The Tegretol series consists of Tegretol slow-release film coated tablets, Tegretol tablets, and Tegretol syrup.

FDA Grants Priority Review to Genentech’s Tecentriq as Adjuvant Treatment for Certain People With Early Non-small Cell Lung Cancer

Retrieved on: 
Tuesday, August 3, 2021
Oncology, FDA, Health, Clinical trials, Pharmaceutical, Biotechnology, Drugs, Breakthrough therapy, Orphan drugs, Health care, Health sciences, Atezolizumab, Cancer immunotherapy, the IMpower010 study, lung cancer, Tecentriq® (atezolizumab), Genentech in cancer immunotherapy, Genentech in lung cancer, Genentech, THE IMPOWER010 STUDY, LUNG CANCER, TECENTRIQ® (ATEZOLIZUMAB), GENENTECH IN CANCER IMMUNOTHERAPY, GENENTECH IN LUNG CANCER, GENENTECH

Tecentriq is the first cancer immunotherapy to show a clinically meaningful benefit in the adjuvant lung cancer setting, and were working closely with the FDA to bring this significant advancement to patients as quickly as possible.

Key Points: 
  • Tecentriq is the first cancer immunotherapy to show a clinically meaningful benefit in the adjuvant lung cancer setting, and were working closely with the FDA to bring this significant advancement to patients as quickly as possible.
  • In this population, median DFS was not yet reached for Tecentriq compared with 35.3 months for BSC.
  • The study randomized 1,005 people with a ratio of 1:1 to receive either Tecentriq (up to 16 cycles) or BSC.
  • These problems may happen anytime during their treatment or even after their treatment has ended.

INVESTOR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Ocugen, Inc. (OCGN) Investors

Retrieved on: 
Tuesday, August 3, 2021
Legal, Professional services, Covaxin, Bharat Biotech, COVID-19, Drugs, Health care, Milberg, Grant & Eisenhofer

Investors have until August 16, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until August 16, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Pursuant to an agreement with Bharat Biotech, Ocugen has the exclusive right to develop, manufacture, and commercialize COVAXIN, a vaccine candidate for COVID-19.
  • Kirby McInerney LLP is a New York-based plaintiffs law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.
  • The firms efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.

Cara Therapeutics to Announce Second Quarter 2021 Financial Results on August 9, 2021

Retrieved on: 
Monday, August 2, 2021
Life sciences, Drugs, Health sciences, Amines, Antipruritics, Difelikefalin, Piperidines, Biopharmaceutical, Investigational New Drug

ET to report second quarter 2021 financial results and provide a corporate update.

Key Points: 
  • ET to report second quarter 2021 financial results and provide a corporate update.
  • To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 1568596.
  • Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral KORs.
  • CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

Mustang Bio Receives European Medicines Agency PRIME Designation for MB-107 to Treat X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants

Retrieved on: 
Monday, August 2, 2021
Life sciences, Health sciences, Health, Pharmaceuticals policy, Drug discovery, Advanced Therapy Medicinal Product, Drugs, Gene therapy, Orphan drug

In addition to PRIME designation, the EMA granted Advanced Therapy Medicinal Product (ATMP) classification to MB-107 in April 2020 and Orphan Drug designation in November 2020.

Key Points: 
  • In addition to PRIME designation, the EMA granted Advanced Therapy Medicinal Product (ATMP) classification to MB-107 in April 2020 and Orphan Drug designation in November 2020.
  • Receiving PRIME designation is an exciting milestone for Mustang as we prepare to initiate a pivotal, multicenter Phase 2 clinical trial of MB-107 in newly diagnosed patients with XSCID at the end of this quarter.
  • To be eligible and accepted for PRIME deisgnation, a treatment has to demonstrate the potential to benefit patients with unmet medical needs based on early clinical data.
  • X-linked severe combined immunodeficiency is a rare genetic disorder that occurs in approximately 1 per 225,000 births.

VYNE Therapeutics Announces Approval of AMZEEQ® (Minocycline) and ZILXI® (Minocycline) in Chinese Economic Pilot Zone

Retrieved on: 
Monday, August 2, 2021
Medicine, Clinical medicine, Cancer research, Hepatotoxins, Otologicals, Tetracycline, Drugs

AMZEEQ and ZILXI were approved for the pilot zone among other innovative dermatology products, said Lele Zhang, CEO of Cutia Therapeutics.

Key Points: 
  • AMZEEQ and ZILXI were approved for the pilot zone among other innovative dermatology products, said Lele Zhang, CEO of Cutia Therapeutics.
  • ZILXI or AMZEEQ should not be used in people who are allergic to ZILXI, AMZEEQ, or any tetracycline medicine.
  • ZILXI and AMZEEQ are flammable and fire, flame, and smoking must be avoided when applying and right after applying ZILXI or AMZEEQ.
  • For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com or follow VYNE on Twitter.